Amanote Research
Register
Sign In
Pss14 - Budget Impact Analysis of Conbercept and Ranibizumab in Patients With Wet Age-Related Macular Degeneration in China
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.09.2514
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2018
Authors
W. Guo
S. Han
Y. Zhang
Publisher
Elsevier BV
Related search
Burden of Wet Age-Related Macular Degeneration in China
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Conbercept for Patients With Age-Related Macular Degeneration: A Systematic Review
BMC Ophthalmology
Medicine
Ophthalmology
Evaluation of Cardiovascular Biomarkers in Patients With Age-Related Wet Macular Degeneration
Clinical Ophthalmology
Ophthalmology
Macular Functional Changes in Patients With Neovascular Age-Related Macular Degeneration Receiving Ranibizumab Therapy (Lucentis)
BMC Geriatrics
Gerontology
Geriatrics
Results of Switchback From Ranibizumab to Aflibercept in Patients With Exudative Age-Related Macular Degeneration
Clinical Ophthalmology
Ophthalmology
Ranibizumab Monotherapy in Neovascular Age-Related Macular Degeneration With Pigment Epithelial Detachment
Journal of Clinical & Experimental Ophthalmology
Ranibizumab Versus Verteporfin for Neovascular Age-Related Macular Degeneration
New England Journal of Medicine
Medicine
Profile of Conbercept in the Treatment Of neovascular Age-Related Macular Degeneration
Drug Design, Development and Therapy
Drug Discovery
Pharmacology
Pharmaceutical Science
PSS10 Cost- Effectiveness of Ranibizumab in Patients With Neovascular Wet Age-Related Macular Degeneration (Namd) at the Mexican Social Security System (Imss)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
